Advertisement
Screener

WINDTREE THERAPEUTICS INC /DE/ (WINT) Preferred Stock Dividends, Income Statement Impact

WINDTREE THERAPEUTICS INC /DE/ Preferred Stock Dividends, Income Statement Impact

WINDTREE THERAPEUTICS INC /DE/ (WINT) reported Preferred Stock Dividends, Income Statement Impact of $1.72 million for the 3-month period ending 2018-12-31, per its 10-K filed 2020-04-03.

Discontinued › Expense Statement › Operating Expenses

us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2020-04-03

  • WINDTREE THERAPEUTICS INC /DE/ preferred stock dividends, income statement impact for the quarter ending 2018-12-31 was $1.72M.
  • WINDTREE THERAPEUTICS INC /DE/ preferred stock dividends, income statement impact for the quarter ending 2017-12-31 was $0.00.
  • WINDTREE THERAPEUTICS INC /DE/ preferred stock dividends, income statement impact for the quarter ending 2017-09-30 was $2.23M.
  • WINDTREE THERAPEUTICS INC /DE/ preferred stock dividends, income statement impact for the quarter ending 2017-06-30 was $532.00K.
  • WINDTREE THERAPEUTICS INC /DE/ preferred stock dividends, income statement impact for fiscal 2018 was $1.72M, a 73.03% decline from fiscal 2017.
  • WINDTREE THERAPEUTICS INC /DE/ preferred stock dividends, income statement impact for fiscal 2017 was $6.37M.
Period endPreferred Stock Dividends, Income Statement Impact 3 monthPreferred Stock Dividends, Income Statement Impact 3 month as first filedPreferred Stock Dividends, Income Statement Impact 6 monthPreferred Stock Dividends, Income Statement Impact 9 monthPreferred Stock Dividends, Income Statement Impact 9 month as first filedPreferred Stock Dividends, Income Statement Impact 12 month
2018-12-31$1.72M
10-K · filed 2020-04-03
$1.72M
10-K · filed 2020-04-03
2017-12-31$0.00
derived: 10-K/A 12 month − 10-Q 9 month · filed 2019-04-23
$2.23M
derived: sum of 2 quarters · filed 2019-04-23
$2.77M
derived: sum of 3 quarters · filed 2019-04-23
$6.37M
10-K/A · filed 2019-04-23
2017-09-30$2.23M
10-K/A · filed 2019-04-23
$1.92M
10-Q · filed 2017-11-14
$2.77M
derived: sum of 2 quarters · filed 2019-04-23
$6.37M
10-Q · filed 2018-11-14
$6.05M
10-Q · filed 2017-11-14
2017-06-30$532.00K
10-K/A · filed 2019-04-23
$4.14M
10-Q · filed 2018-08-14
2017-03-31$3.60M
10-K · filed 2020-04-03
$3.60M
10-Q · filed 2017-05-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
VivoSim Labs, INC. (VIVS)United States$0.003B
Calidi Biotherapeutics, Inc. (CLDI)United States$0.003B
PharmaCyte Biotech, Inc. (PMCB)United States$0.005B
CURIS INC (CRIS)United States$0.002B-0.05
Silexion Therapeutics Corp (SLXN)$0.001B
AIM ImmunoTech Inc. (AIM)United States$0.006B
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)United States$0.006B
CERO THERAPEUTICS HOLDINGS, INC. (CERO)United States$0.007B
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70